Interleukin-1, neuroinflammation, and Alzheimer's disease

被引:293
作者
Mrak, RE [1 ]
Griffin, WST
机构
[1] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA
[3] Dept Vet Affairs Med Ctr, Little Rock, AR 72205 USA
关键词
A beta plaques; A beta precursor protein; aging; Alzheimer's disease; astrocytes; Down's syndrome; head trauma; IL-1; microglia; neuritic plaques; S100B;
D O I
10.1016/S0197-4580(01)00287-1
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Interleukin-1 (IL-1)-1) is a pluripotent immunomodulatory cytokine that has an initiating role in cellular and humoral immunity in the periphery. IL-1 is overexpressed in Alzheimer brain, and this overexpression is directly related to plaque formation and progression, nonsensical growth of dystrophic neurites, and neuronal overexpression of acetylcholinesterase. IL-1 has a number of actions relevant to Alzheimer's disease, including excessive expression of neuronal Ap precursor protein and other plaque-associated proteins, and induction of astrocyte activation and astrocytic overexpression of S100B. These latter events may be related to the overgrowth of dystrophic neurites in neuritic plaques, a necessary event for conversion of diffuse A beta deposits into the neuritic amyloid plaques diagnostic of Alzheimer's disease. Four new genetic studies underscore the relevance of IL-1 to Alzheimer pathogenesis, showing that homozygosity of a specific polymorphism in the IL-1A gene at least triples Alzheimer risk, especially for an earlier age of onset and in combination with homozygosity for another polymorphism in the IL-1B gene. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:903 / 908
页数:6
相关论文
共 73 条
[1]   A randomized controlled trial of prednisone in Alzheimer's disease [J].
Aisen, PS ;
Davis, KL ;
Berg, JD ;
Schafer, K ;
Campbell, K ;
Thomas, RG ;
Weiner, MF ;
Farlow, MR ;
Sano, M ;
Grundman, M ;
Thal, LJ .
NEUROLOGY, 2000, 54 (03) :588-593
[2]   DO NONSTEROIDAL ANTIINFLAMMATORY DRUGS DECREASE THE RISK FOR ALZHEIMERS-DISEASE - THE ROTTERDAM STUDY [J].
ANDERSEN, K ;
LAUNER, LJ ;
OTT, A ;
HOES, AW ;
BRETELER, MMB ;
HOFMAN, A .
NEUROLOGY, 1995, 45 (08) :1441-1445
[3]  
[Anonymous], CYTOKINE
[4]  
AURON PE, 1994, EUR CYTOKINE NETW, V5, P573
[5]   Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E [J].
Barger, SW ;
Harmon, AD .
NATURE, 1997, 388 (6645) :878-881
[6]  
BARGER SW, 1992, J BIOL CHEM, V267, P9689
[7]   Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies [J].
Bertram, L ;
Blacker, D ;
Crystal, A ;
Mullin, K ;
Keeney, D ;
Jones, J ;
Basu, S ;
Yhu, S ;
Guénette, S ;
McInnis, M ;
Go, R ;
Tanzi, R .
EXPERIMENTAL GERONTOLOGY, 2000, 35 (9-10) :1353-1361
[8]   DELAYED-ONSET OF ALZHEIMERS-DISEASE WITH NONSTEROIDAL ANTIINFLAMMATORY AND HISTAMINE-H2 BLOCKING-DRUGS [J].
BREITNER, JCS ;
WELSH, KA ;
HELMS, MJ ;
GASKELL, PC ;
GAU, BA ;
ROSES, AD ;
PERICAKVANCE, MA ;
SAUNDERS, AM .
NEUROBIOLOGY OF AGING, 1995, 16 (04) :523-530
[9]   INVERSE ASSOCIATION OF ANTIINFLAMMATORY TREATMENTS AND ALZHEIMERS-DISEASE - INITIAL RESULTS OF A COTWIN CONTROL STUDY [J].
BREITNER, JCS ;
GAU, BA ;
WELSH, KA ;
PLASSMAN, BL ;
MCDONALD, WM ;
HELMS, MJ ;
ANTHONY, JC .
NEUROLOGY, 1994, 44 (02) :227-232
[10]   CHOLINERGIC AGONISTS AND INTERLEUKIN-1 REGULATE PROCESSING AND SECRETION OF THE ALZHEIMER BETA/A4 AMYLOID PROTEIN-PRECURSOR [J].
BUXBAUM, JD ;
OISHI, M ;
CHEN, HI ;
PINKASKRAMARSKI, R ;
JAFFE, EA ;
GANDY, SE ;
GREENGARD, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) :10075-10078